Mass spectrometry-based proteomics: The road to lung cancer biomarker discovery

Mass Spectrometry Reviews

Volumn 32, Issue 2, 2013, Pages 129-142

  Indovina, Paola ^a,b   Marcelli, Eleonora ^a   Pentimalli, Francesca ^c   Tanganelli, Piero ^a   Tarro, Giulio ^b,d,e   Giordano, Antonio ^a,b,c  

^a UNIVERSITY OF SIENA   (Italy)

^b Temple University   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Fondazione T   (Italy)

^e UNESCO   (France)

Author keywords

biomarkers; diagnosis; lung cancer; predictive markers; prognosis; proteomics

Indexed keywords

CANCER DEVELOPMENT; CLINICAL MANAGEMENT; LUNG CANCER; MOLECULAR MECHANISM; PREDICTIVE MARKERS; PROGNOSIS; PROTEOMICS; PROTEOMICS TECHNOLOGY; REPRODUCIBILITIES; SURVIVAL RATE; THERAPEUTIC STRATEGY; THERAPEUTIC TARGETS;

BIOLOGICAL ORGANS; BIOMARKERS; DIAGNOSIS; MASS SPECTROMETRY; MOLECULAR BIOLOGY; PROTEINS;

DISEASES;

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; TUMOR MARKER;

ANIMAL; BLOOD; CHEMISTRY; DRUG EFFECT; ELECTROSPRAY MASS SPECTROMETRY; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG TUMOR; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PLEURA EFFUSION; PROGNOSIS; PROTEIN PROCESSING; PROTEOMICS; REVIEW; SALIVA; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLYCOSYLATION; HUMANS; LUNG NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOMICS; SALIVA; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84874251073     PISSN: 02777037     EISSN: 10982787     Source Type: Journal    
DOI: 10.1002/mas.21355     Document Type: Review

References (116)

1. Alfonso P, Catalá M, Rico-Morales ML, Durante-Rodríguez G, Moro-Rodríguez E, Fernández-García H, Escribano JM, Alvarez-Fernández E, García-Poblete E,. 2004. Proteomic analysis of lung biopsies: Differential protein expression profile between peritumoral and tumoral tissue. Proteomics 4: 442-447.
2. An HJ, Kronewitter SR, de Leoz ML, Lebrilla CB,. 2009. Glycomics and disease markers. Curr Opin Chem Biol 13: 601-607.
3. Au JS, Cho WC, Yip TT, Yip C, Zhu H, Leung WW, Tsui PY, Kwok DL, Kwan SS, Cheng WW, Tzang LC, Yang M, Law SC,. 2007. Deep proteome profiling of sera from never-smoked lung cancer patients. Biomed Pharmacother 61: 570-577.
4. Benkmann HG, Hanssen HP, Ovenbeck R, Goedde HW,. 1987. Distribution of alpha-1-antitrypsin and haptoglobin phenotypes in bladder cancer patients. Hum Hered 37: 290-293.
5. Bergman AC, Benjamin T, Alaiya A, Waltham M, Sakaguchi K, Franzén B, Linder S, Bergman T, Auer G, Appella E, Wirth PJ, Jörnvall H,. 2000. Identification of gel-separated tumor marker proteins by mass spectrometry. Electrophoresis 21: 679-686.
6. Bieche I, Lachkar S, Becette V, Cifuentes-Diaz C, Sobel A, Lidereau R, Curmi PA,. 1998. Overexpression of the stathmin gene in a subset of human breast cancer. Br J Cancer 78: 701-709.
7. Biran H, Friedman N, Neumann L, Pras M, Shainkin-Kestenbaum R,. 1986. Serum amyloid A (SAA) variations in patients with cancer: Correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 39: 794-797.
8. Brattsand G,. 2000. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 83: 311-318.
9. Brevet M, Johnson ML, Azzoli CG, Ladanyi M,. 2011. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 73: 96-102.
10. Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EF Jr., 2003. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin A as potential molecular targets in non-small cell lung cancer. Cancer Res 63: 1652-1656.
11. Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, Kardia SL, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG,. 2002. Proteomic analysis of lung adenocarcinoma: Identification of a highly expressed set of proteins in tumors. Clin Cancer Res 8: 2298-2305.
12. Chen G, Gharib TG, Wang H, Huang CC, Kuick R, Thomas DG, Shedden KA, Misek DE, Taylor JM, Giordano TJ, Kardia SL, Iannettoni MD, Yee J, Hogg PJ, Orringer MB, Hanash SM, Beer DG,. 2003a. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci USA 100: 13537-13542.
13. Chen G, Wang H, Gharib TG, Huang CC, Thomas DG, Shedden KA, Kuick R, Taylor JM, Kardia SL, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG,. 2003b. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2: 107-116.
14. Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS, Kleinman HK,. 1993. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 91: 977-985.
15. Conroy H, Mawhinney L, Donnelly SC,. 2010. Inflammation and cancer: Macrophage migration inhibitory factor (MIF)-the potential missing link J Med 103: 831-836.
16. Curmi PA, Nogues C, Lachkar S, Carelle N, Gonthier MP, Sobel A, Lidereau R, Bieche I,. 2000. Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer 82: 142-150.
17. Davies AM, Lara PN Jr, Mack PC, Gandara DR,. 2007. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 13: 4647-4651.
18. de Kleijn DP, Smeets MB, Kemmeren PP, Lim SK, Middelaar Van BJ, Velema E, Schoneveld A, Pasterkamp G, Borst C,. 2002. Acute-phase protein haptoglobin is a cell migration factor involved in arterial restructuring. FASEB J 16: 1123-1125.
19. De Petris L, Brandén E, Herrmann R, Sanchez BC, Koyi H, Linderholm B, Lewensohn R, Linder S, Lehtiö J,. 2011. Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer. Eur J Cancer 47: 131-137.
20. De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, Lehtiö J,. 2009. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer. Lung Cancer 63: 410-417.
21. Diamandis EP,. 2003. Point: Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics? Clin Chem 49: 1272-1275.
22. Du J, Yang SY, Lin XL, Shang WL, Zhang W, Huo SF, Bu LN, Zhang W, Zhou B, Nan YD, Zheng HD, Liu YF,. 2011. Biomarker discovery and identification from non-small cell lung cancer sera. Front Biosci (Elite Ed) 3: 1-10.
23. Dunzendorfer U, Jung K, Ohlenschläger G,. 1980. Transferrin, C3 complement, haptoglobin, plasminogen and alpha 2-microglobulin in patients with urogenital tumors. Eur Urol 6: 232-236.
24. Emberley ED, Murphy LC, Watson PH,. 2004. S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol 82: 508-515.
25. Epelbaum R, Shalitin C, Segal R, Valansi C, Arselan I, Faraggi D, Leviov M, Ben-Shahar M, Haim N,. 1998. Haptoglobin-related protein as a serum marker in malignant lymphoma. Pathol Oncol Res 4: 271-276.
26. Falvella FS, Spinola M, Pignatiello C, Noci S, Conti B, Pastorino U, Carbone A, Dragani TA,. 2008. AZGP1 mRNA levels in normal human lung tissue correlate with lung cancer disease status. Oncogene 27: 1650-1656.
27. Firpo MA, Gay DZ, Granger SR, Scaife CL, DiSario JA, Boucher KM, Mulvihill SJ,. 2009. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg 33: 716-722.
28. Friedrich B, Gronberg H, Landstrom M, Gullberg M, Bergh A,. 1995. Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. Prostate 27: 102-109.
29. Gámez-Pozo A, Sánchez-Navarro I, Nistal M, Calvo E, Madero R, Díaz E, Camafeita E, de Castro J, Lõpez JA, González- Barõn M, Espinosa E, Fresno Vara JA,. 2009. MALDI profiling of human lung cancer subtypes. PLoS ONE 4: e7731.
30. Gao K, Zhou H, Zhang L, Lee JW, Zhou Q, Hu S, Wolinsky LE, Farrell J, Eibl G, Wong T,. 2009. Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer. PLoS ONE 4: e5875.
31. Gewinner C, Hart G, Zachara N, Cole R, Beisenherz-Huss C, Groner B,. 2004. The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. J Biol Chem 279: 3563-3572.
32. Gharib TG, Chen G, Wang H, Huang CC, Prescott MS, Shedden K, Misek DE, Thomas DG, Giordano TJ, Taylor JM, Kardia S, Yee J, Orringer MB, Hanash S, Beer DG,. 2002. Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. Neoplasia 4: 440-448.
33. Görg A, Weiss W, Dunn MJ,. 2004. Current two-dimensional electrophoresis technology for proteomics. Proteomics 4: 3665-3685.
34. Granville CA, Dennis PA,. 2005. An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 32: 169-176.
35. Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T,. 2011. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer 71: 249-257.
36. Hailat N, Strahler J, Melhem R, Zhu XX, Brodeur G, Seeger R, Reynolds CP, Hanash S,. 1990. N-myc gene amplification in neuroblastoma is associated with altered phosphorylation of a proliferation related polypeptide (Op18). Oncogene 5: 1615-1618.
37. Hamrita B, Chahed K, Trimeche M, Guillier CL, Hammann P, Chaïeb A, Korbi S, Chouchane L,. 2009. Proteomics-based identification of alpha1-antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas. Clin Chim Acta 404: 111-118.
38. Han KQ, Huang G, Gao CF, Wang XL, Ma B, Sun LQ, Wei ZJ,. 2008. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Am J Clin Oncol 31: 133-139.
39. Han M, Liu Q, Yu J, Zheng S,. 2010. Identification of candidate molecular markers predicting chemotherapy resistance in non-small cell lung cancer. Clin Chem Lab Med 48: 863-867.
40. Heo SH, Lee SJ, Ryoo HM, Park JY, Cho JY,. 2007. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics 7: 4292-4302.
41. Hirsch J, Hansen KC, Burlingame AL, Matthay MA,. 2004. Proteomics: Current techniques and potential applications to lung disease. Am J Physiol Lung Cell Mol Physiol 287: 1-23.
42. Howard BA, Wang MZ, Campa MJ, Corro C, Fitzgerald MC, Patz EF Jr., 2003. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics 3: 1720-1724.
43. Hsu PS, Wang YS, Huang SC, Lin YH, Chang CC, Tsang YW, Jiang JS, Kao SJ, Uen WC, Chi KH,. 2011. Improving detection accuracy of lung cancer serum proteomic profiling via two-stage training process. Proteome Sci 9: 20.
44. Hu S, Loo JA, Wong DT,. 2007. Human saliva proteome analysis and disease biomarker discovery. Expert Rev Proteomics 4: 531-538.
45. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. 2009. Cancer statistics. CA Cancer J Clin 59: 225-249.
46. Joo JH, Yoon SY, Kim JH, Paik SG, Min SR, Lim JS, Choe IS, Choi I, Kim JW,. 2008. S100A6 (calcyclin) enhances the sensitivity to apoptosis via the upregulation of caspase-3 activity in Hep3B cells. J Cell Biochem 103: 1183-1197.
47. Kang SM, Sung HJ, Ahn JM, Park JY, Lee SY, Park CS, Cho JY,. 2011. The haptoglobin β chain as a supportive biomarker for human lung cancers. Mol Biosyst 7: 1167-1175.
48. Kikuchi T, Carbone DP,. 2007. Proteomics analysis in lung cancer: Challenges and opportunities. Respirology 12: 22-28.
49. Larsson N, Melander H, Marklund U, Osterman O, Gullberg M,. 1995. G2/M transition requires multisite phosphorylation of oncoprotein 18 by two distinct protein kinase systems. J Biol Chem 270: 14175-14183.
50. Lee J, Kim SS,. 2010. Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res 19: 29-97.
51. Lehtiö J, De Petris L,. 2010. Lung cancer proteomics, clinical and technological considerations. J Proteomics 73: 1851-1863.
52. Liu YF, Xiao ZQ, Li MX, Li MY, Zhang PF, Li C, Li F, Chen YH, Yi H, Yao HX, Chen ZC,. 2009. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol 217: 54-64.
53. Ludwig H, Khayat D, Giaccone G, Facon T,. 2005. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104: 1794-1807.
54. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA,. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
55. Maeda J, Hirano T, Ogiwara A, Akimoto S, Kawakami T, Fukui Y, Oka T, Gong Y, Guo R, Inada H, Nawa K, Kojika M, Suga Y, Ohira T, Mukai K, Kato H,. 2008. Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualization of postoperative therapy. Br J Cancer 98: 596-603.
56. Matta A, Ralhan R, DeSouza LV, Siu KW,. 2010. Mass spectrometry-based clinical proteomics: Head-and-neck cancer biomarkers and drug-targets discovery. Mass Spectrom Rev 29: 945-961.
57. McDonnell LA, Corthals GL, Willems SM, van Remoortere A, van Zeijl RJ, Deelder AM,. 2010. Peptide and protein imaging mass spectrometry in cancer research. J Proteomics 73: 1921-1944.
58. Monari E, Casali C, Cuoghi A, Nesci J, Bellei E, Bergamini S, Fantoni LI, Natali P, Morandi U, Tomasi A,. 2011. Enriched sera protein profiling for detection of non-small cell lung cancer biomarkers. Proteome Sci 9: 55.
59. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ,. 2004. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Chemother Pharmacol 54: 343-353.
60. Narayanasamy A, Ahn JM, Sung HJ, Kong DH, Ha KS, Lee SY, Cho JY,. 2011. Fucosylated glycoproteomic approach to identify a complement component 9 associated with squamous cell lung cancer (SQLC). J Proteomics 74: 2948-2958.
61. Nilsson T, Mann M, Aebersold R, Yates JR III, Bairoch A, Bergeron JJ,. 2010. Mass spectrometry in high-throughput proteomics: Ready for the big time. Nat Methods 7: 681-685.
62. Nylander K, Marklund U, Brattsand G, Gullberg M, Roos G,. 1995. Immunohistochemical detection of oncoprotein 18 (Op18) in malignant lymphomas. Histochem J 27: 155-160.
63. Ocak S, Chaurand P, Massion PP,. 2009. Mass spectrometry-based proteomic profiling of lung cancer. Proc Am Thorac Soc 6: 159-170.
64. Oh JM, Brichory F, Puravs E, Kuick R, Wood C, Rouillard JM, Tra J, Kardia S, Beer D, Hanash S,. 2001. A database of protein expression in lung cancer. Proteomics 1: 1303-1319.
65. Okano T, Kondo T, Fujii K, Nishimura T, Takano T, Ohe Y, Tsuta K, Matsuno Y, Gemma A, Kato H, Kudoh S, Hirohashi S,. 2007. Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Clin Cancer Res 13: 799-805.
66. Oshiro S, Yajima Y, Kawamura K, Kubota M, Yokofujita J, Nishibe Y, Takahama M, Nakajima H,. 1992. Catabolism of hemoglobin-haptoglobin complex in microsome subfractions. Chem Pharm Bull (Tokyo) 40: 1847-1851.
67. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P,. 1995. Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 13: 1221-1230.
68. Pang WW, Abdul-Rahman PS, Wan-Ibrahim WI, Hashim OH,. 2010. Can the acute-phase reactant proteins be used as cancer biomarkers? Int J Biol Markers 25: 1-11.
69. Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE,. 2007. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 25: 5578-5583.
70. Pawa N, Wright JM, Arulampalam TH,. 2010. Mass spectrometry based proteomic profiling for pancreatic cancer. JOP 11: 423-426.
71. Pernemalm M, De Petris L, Eriksson H, Brandén E, Koyi H, Kanter L, Lewensohn R, Lehtiö J,. 2009. Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion. Proteomics 9: 3414-3424.
72. Price DK, Ball JR, Bahrani-Mostafavi Z, Vachris JC, Kaufman JS, Naumann RW, Higgins RV, Hall JB,. 2000. The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Investig 18: 722-730.
73. Qi J, Liu N, Zhou Y, Tan Y, Cheng Y, Yang C, Zhu Z, Xiong D,. 2006. Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis. Biochem Biophys Res Commun 349: 303-309.
74. Qu Y, Yang Y, Liu B, Xiao W,. 2010. Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer. Med Oncol 27: 1303-1308.
75. Rahman SM, Shyr Y, Yildiz PB, Gonzalez AL, Li H, Zhang X, Chaurand P, Yanagisawa K, Slovis BS, Miller RF, Ninan M, Miller YE, Franklin WA, Caprioli RM, Carbone DP, Massion PP,. 2005. Proteomic patterns of preinvasive bronchial lesions. Am J Respir Crit Care Med 172: 1556-1562.
76. Reguart N, Cardona AF, Rosell R,. 2010. Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer. Cancer Manag Res 2: 143-156.
77. Rodríguez-Piñeiro AM, Blanco-Prieto S, Sánchez-Otero N, Rodríguez-Berrocal FJ, de la Cadena MP,. 2010. On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. J Proteomics 73: 1511-1522.
78. Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, Sandler A, Billheimer D, Shyr Y, Lee JW, Massion P, Brahmer J, Schiller J, Carbone D, Dang TP,. 2009. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol 4: 689-696.
79. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH,. 2002. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98.
80. Soltermann A, Ossola R, Kilgus-Hawelski S, von Eckardstein A, Suter T, Aebersold R, Moch H,. 2008. N-glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics. Cancer 114: 124-133.
81. Song QB, Hu WG, Wang P, Yao Y, Zeng HZ,. 2011. Identification of serum biomarkers for lung cancer using magnetic bead-based SELDI-TOF-MS. Acta Pharmacol Sin 32: 1537-1542.
82. Stroncek DF, Burns C, Martin BM, Rossi L, Marincola FM, Panelli MC,. 2005. Advancing cancer biotherapy with proteomics. J Immunother 28: 183-192.
83. Su YJ, Xu F, Yu JP, Yue DS, Ren XB, Wang CL,. 2010. Up-regulation of the expression of S100A8 and S100A9 in lung adenocarcinoma and its correlation with inflammation and other clinical features. Chin Med J (Engl) 123: 2215-2220.
84. Sung HJ, Cho JY,. 2008. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 41: 615-625.
85. Sung HJ, Ahn JM, Yoon YH, Rhim TY, Park CS, Park JY, Lee SY, Kim JW, Cho JY,. 2011. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res 10: 1383-1395.
86. Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Kelly-Spratt K, Wong CH, Zhang Q, Chin A, Park KS, Goodman G, Gazdar AF, Sage J, Dinulescu DM, Kucherlapati R, Depinho RA, Kemp CJ, Varmus HE, Hanash SM,. 2011. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 20: 289-299.
87. Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR Jr, Bunn PA, Carbone DP,. 2007. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study. J Natl Cancer Inst 99: 838-846.
88. Tan HT, Lee YH, Chung MC,. 2012. Cancer proteomics. Mass Spectrom Rev [Epub ahead of print], DOI: 10.1002/mas.20356.
89. Tang SJ, Ho MY, Cho HC, Lin YC, Sun GH, Chi KH, Wang YS, Jhou RS, Yang W, Sun KH,. 2008. Phosphoglycerate kinase 1-overexpressing lung cancer cells reduce cyclooxygenase 2 expression and promote anti-tumor immunity in vivo. Int J Cancer 123: 2840-2848.
90. Tarro G, Perna A, Esposito C,. 2005. Early diagnosis of lung cancer by detection of tumor liberated protein. J Cell Physiol 203: 1-5.
91. Tarro G,. 2009. Tumor liberated protein from lung cancer and perspectives for immunotherapy. J Cell Physiol 221: 26-30.
92. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J,. 1999. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5: 2638-2645.
93. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG,. 2000. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
94. Tian T, Hao J, Xu A, Hao J, Luo C, Liu C, Huang L, Xiao X, He D,. 2007. Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis. Cancer Sci 98: 1265-1274.
95. Tong L, Baskaran G, Jones MB, Rhee JK, Yarema KJ,. 2003. Glycosylation changes as markers for the diagnosis and treatment of human disease. Biotechnol Genet Eng Rev 20: 199-244.
96. Tsai HY, Boonyapranai K, Sriyam S, Yu CJ, Wu SW, Khoo KH, Phutrakul S, Chen ST,. 2011. Glycoproteomics analysis to identify a glycoform on haptoglobin associated with lung cancer. Proteomics 11: 2162-2170.
97. Tyan YC, Wu HY, Lai WW, Su WC, Liao PC,. 2005a. Proteomic profiling of human pleural effusion using two-dimensional nano liquid chromatography tandem mass spectrometry. J Proteome Res 4: 1274-1286.
98. Tyan YC, Wu HY, Su WC, Chen PW, Liao PC,. 2005b. Proteomic analysis of human pleural effusion. Proteomics 5: 1062-1074.
99. Ueda K, Fukase Y, Katagiri T, Ishikawa N, Irie S, Sato TA, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Shiwa M, Nakamura Y, Daigo Y,. 2009. Targeted serum glycoproteomics for the discovery of lung cancer-associated glycosylation disorders using lectin-coupled ProteinChip arrays. Proteomics 9: 2182-2192.
100. Uhlar CM, Whitehead AS,. 1999. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265: 501-523.
101. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P,. 2006. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116: 271-284.
102. Voortman J, Pham TV, Knol JC, Giaccone G, Jimenez CR,. 2009. Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling. Proteome Sci 7: 34.
103. Wu X, Xiao Z, Chen Z, Li C, Li J, Feng X, Yi H, Liang S, Chen P,. 2004. Differential analysis of two-dimension gel electrophoresis profiles from the normal-metaplasia-dysplasia-carcinoma tissue of human bronchial epithelium. Pathol Int 54: 765-773.
104. Xiao H, Zhang L, Zhou H, Lee JM, Garon EB, Wong DT,. 2011. Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol Cell Proteomics 11: 1862-1867.
105. Xiao X, Liu D, Tang Y, Guo F, Xia L, Liu J, He D,. 2003-2004. Development of proteomic patterns for detecting lung cancer. Dis Markers 19: 33-39.
106. Xu A, Hao J, Zhang Z, Tian T, Jiang S, Hao J, Liu C, Huang L, Xiao X, He D,. 2010. 14-kDa phosphohistidine phosphatase and its role in human lung cancer cell migration and invasion. Lung Cancer 67: 48-56.
107. Xu BJ, Gonzalez AL, Kikuchi T, Yanagisawa K, Massion PP, Wu H, Mason SE, Olson SJ, Shyr Y, Carbone DP, Caprioli RM,. 2008. MALDI-MS derived prognostic protein markers for resected non-small cell lung cancer. Proteomics Clin Appl 2: 1508-1517.
108. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM, Carbone DP,. 2003. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 9: 433-439.
109. Yanagisawa K, Tomida S, Shimada Y, Yatabe Y, Mitsudomi T, Takahashi T,. 2007. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst 99: 858-867.
110. Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B, Chen G, He DC,. 2005. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 20: 5-83.
111. Yao H, Zhang Z, Xiao Z, Chen Y, Li C, Zhang P, Li M, Liu Y, Guan Y, Yu Y, Chen Z,. 2009. Identification of metastasis associated proteins in human lung squamous carcinoma using two-dimensional difference gel electrophoresis and laser capture microdissection. Lung Cancer 65: 41-48.
112. Yildiz PB, Shyr Y, Rahman JS, Wardwell NR, Zimmerman LJ, Shakhtour B, Gray WH, Chen S, Li M, Roder H, Liebler DC, Bigbee WL, Siegfried JM, Weissfeld JL, Gonzalez AL, Ninan M, Johnson DH, Carbone DP, Caprioli RM, Massion PP,. 2007. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol 2: 893-901.
113. Zalcman G, Bergot E, Lechapt E,. 2010. Update on nonsmall cell lung cancer. Eur Respir Rev 19: 173-185.
114. Zeng X, Hood BL, Sun M, Conrads TP, Day RS, Weissfeld JL, Siegfried JM, Bigbee WL,. 2010. Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. J Proteome Res 9: 6440-6449. Epub 2010 Oct 28.
115. Zhao C, Annamalai L, Guo C, Kothandaraman N, Koh SC, Zhang H, Biswas A, Choolani M,. 2007. Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia 9: 1-7.
116. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS,. 2003. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 40: 267-279.